A PHASE I-IB/II, OPEN-LABEL, MULTI-CENTER STUDY OF THE SAFETY AND EFFICACY OF MBG453 AS SINGLE AGENT AND IN COMBINATION WITH PDR001 IN ADULT PATIENTS WITH ADVANCED MALIGNANCIES

Registry ID

CMBG453X2101

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

NOVARTIS PHARMACEUTICALS CANADA INC

Start date

2016-10-17

Last update

2015-11-27

Conditions

• ADVANCED MALIGNANCIES

Related clinical trials

• A PHASE 1/1B FIRST-IN-HUMAN TRIAL OF BMS-986484 AS MONOTHERAPY AND COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID MALIGNANCIES
• AN OPEN-LABEL PHASE 1 STUDY TO EVALUATE THE SAFETY OF SGN 35T IN ADULTS WITH ADVANCED MALIGNANCIES
• AN OPEN-LABEL, PHASE 2 BASKET STUDY OF SEA-CD40 COMBINATION THERAPIES IN ADVANCED MALIGNANCIES
• PHASE I/II STUDY OF THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY CLINICAL ACTIVITY OF BT8009 IN PATIENTS WITH NECTIN-4 EXPRESSING ADVANCED MALIGNANCIES
• AN OPEN-LABEL, MULTICENTER, DOSE ESCALATION PHASE LB STUDY TO ASSESS THE SAFETY AND PHARMACOKINETICS OF SUBCUTANEOUS DELIVERY OF AMIVANTAMAB, A HUMAN BISPECIFIC EGFR AND CMET ANTIBODY FOR THE TREATMENT OF ADVANCED SOLID MALIGNANCIES
• CANADIAN ATEZOLIZUMAB PRECISION TARGETING FOR IMMUNOTHERAPY INTERVENTION: CAPTIV-8.

View on source registry